Weight loss drugs sold by Eli Lilly (LLY) and Novo Nordisk (NVO) were deemed cost effective by the Institute for Clinical and Economic Review, a nonprofit that assesses the value of medicines. ICER noted that Novo Nordisk’s Wegovy has a net price of $6,829, while Lilly’s Zepbound is priced at $7,973 and calculated a health benefit price benchmark to be between $9,100 and $12,500 for Wegovy and between $11,500 and $15,800 for Zepbound.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- New Walmart and Eli Lilly Partnership Puts Weight Loss Drugs on the Shopping List
- Eli Lilly, Walmart launch first retail pick-up option
- Nvidia Stock (NVDA) Hits All-Time High after Barrage of AI and Supercomputing Deals
- Lilly partners with Nvidia to build AI supercomputer, medicine discovery
- Adverum Biotechnologies price target raised to $4 from $3 at RBC Capital